Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$22.21
Price-4.06%
-$0.94
1Y
Price
Market Cap
$2.254b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1142.8%
EBITDA Margin-1208.3%
Net Profit Margin-940.1%
Free Cash Flow MarginRevenue
$60.272m
-5.1%
1y CAGR+143.9%
3y CAGR+112.3%
5y CAGREarnings
-$398.583m
-5.8%
1y CAGR-46.8%
3y CAGR-29.4%
5y CAGREPS
-$4.50
+1.8%
1y CAGR-36.8%
3y CAGR-20.3%
5y CAGRBook Value
$1.047b
$1.391b
Assets$344.344m
Liabilities$154.803m
DebtDebt to Assets
11.1%
-0.4x
Debt to EBITDAFree Cash Flow
-$355.572m
+0.2%
1y CAGR-228.9%
3y CAGR-152.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company